News
The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...
News-Medical.Net on MSN9h
First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trialThe first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback